Just a hypothetical question. Deployable applications, which include the ability to enforce user fixed/floating licenses, are available to partners/ISVs.
Partners are not allowed to write competing products. Does this mean that companies/people attempting to write apps that are similar in nature to those that Remedy offers are in a catch22 situation? Axton Grams _______________________________________________________________________________ UNSUBSCRIBE or access ARSlist Archives at www.arslist.org ARSlist:"Where the Answers Are"
